OBJECTIVE: This study is designed to (1) determine the perceived quality of care received by patients with head and neck cancer at the end of their lives, in order to (2) better anticipate and improve upon the experiences of future patients. STUDY DESIGN: Cross-sectional survey. SETTING: Single-institution, academic tertiary care medical center. SUBJECTS AND METHODS: A validated survey instrument, the Family Assessment of Treatment at the End of life (FATE), was administered to families of patients who died of head and neck cancer (n = 58). The primary outcome was the overall FATE score. Independent variables included clinical characteristics, treatments received, and the care provided at the time of death. RESULTS: Overall FATE scores and the domains assessing management of symptoms and care at the time of death did not vary by disease status (logoregional vs distant metastasis) at the end of life (P = .989). The location of death in the home or in hospice (vs hospital) significantly improves scores in all 3 categories (P = .023). Involvement of a palliative care team improved the care at the time of death (P < .001), and palliative treatments (radiation and/or chemotherapy) improved scores in managing symptoms and care at the time of death (P = .011, P = .017). CONCLUSION: The FATE survey is a useful measure of the end-of-life experience of head and neck cancer patients. Palliative treatments of head and neck cancer, death outside of the hospital, and palliative care team involvement all improve the end-of-life experience in this population.
OBJECTIVE: This study is designed to (1) determine the perceived quality of care received by patients with head and neck cancer at the end of their lives, in order to (2) better anticipate and improve upon the experiences of future patients. STUDY DESIGN: Cross-sectional survey. SETTING: Single-institution, academic tertiary care medical center. SUBJECTS AND METHODS: A validated survey instrument, the Family Assessment of Treatment at the End of life (FATE), was administered to families of patients who died of head and neck cancer (n = 58). The primary outcome was the overall FATE score. Independent variables included clinical characteristics, treatments received, and the care provided at the time of death. RESULTS: Overall FATE scores and the domains assessing management of symptoms and care at the time of death did not vary by disease status (logoregional vs distant metastasis) at the end of life (P = .989). The location of death in the home or in hospice (vs hospital) significantly improves scores in all 3 categories (P = .023). Involvement of a palliative care team improved the care at the time of death (P < .001), and palliative treatments (radiation and/or chemotherapy) improved scores in managing symptoms and care at the time of death (P = .011, P = .017). CONCLUSION: The FATE survey is a useful measure of the end-of-life experience of head and neck cancerpatients. Palliative treatments of head and neck cancer, death outside of the hospital, and palliative care team involvement all improve the end-of-life experience in this population.
Authors: Madanagopalan Ethunandan; Andrew Rennie; Gary Hoffman; Paula J Morey; Peter A Brennan Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2005-08
Authors: David Casarett; Amy Pickard; F Amos Bailey; Christine Ritchie; Christian Furman; Ken Rosenfeld; Scott Shreve; Zhen Chen; Judy A Shea Journal: J Am Geriatr Soc Date: 2008-01-16 Impact factor: 5.562
Authors: Quirine C P Ledeboer; Marinella P J Offerman; Lilly-Ann van der Velden; Maarten F de Boer; Jean F A Pruyn Journal: Head Neck Date: 2008-04 Impact factor: 3.147
Authors: Abrahim Al-mamgani; Lisa Tans; Peter H E Van rooij; Inge Noever; Robert J Baatenburg de jong; Peter C Levendag Journal: Acta Oncol Date: 2009 Impact factor: 4.089
Authors: Andreas M Sesterhenn; Benedikt J Folz; Michael Bieker; Afshin Teymoortash; Jochen A Werner Journal: Cancer Nurs Date: 2008 Mar-Apr Impact factor: 2.592
Authors: David Casarett; Amy Pickard; F Amos Bailey; Christine Seel Ritchie; Christian Davis Furman; Ken Rosenfeld; Scott Shreve; Judy Shea Journal: J Palliat Med Date: 2008 Jan-Feb Impact factor: 2.947
Authors: N J H Raijmakers; L van Zuylen; C J Furst; M Beccaro; L Maiorana; P Pilastri; C Rossi; G Flego; A van der Heide; M Costantini Journal: Support Care Cancer Date: 2012-10-14 Impact factor: 3.603
Authors: Emmanuel Kabengele Mpinga; Véronique Delley; Emilien Jeannot; Joachim Cohen; Philippe Chastonay; Donna M Wilson Journal: Glob J Health Sci Date: 2013-09-26